GS
BMRN icon

GTS Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

GTS Securities’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-53,600
Closed -$3.77M – 1600
2024
Q3 		$3.77M Sell
53,600
-11,700
-18% -$978K 0.01% 1094
2024
Q2 		$5.38M Buy
65,300
+15,000
+30% +$1.25M 0.01% 822
2024
Q1 		$4.39M Buy
50,300
+12,700
+34% +$1.14M 0.01% 955
2023
Q4 		$3.63M Buy
37,600
+16,800
+81% +$1.49M 0.01% 1224
2023
Q3 		$1.84M Buy
+20,800
New +$1.85M ﹤0.01% 1577

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

GTS Securities's BMRN Position: Q4 2024 in Review

GTS Securities sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 34,440 shares — an estimated $2.42M sold.

GTS Securities first reported a position in BMRN in Q2 2023 and held it in 6 quarters. The position peaked at $2.59M in Q4 2023. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • GTS Securities reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 34,440 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $2.42M.
  • GTS Securities first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • GTS Securities's BioMarin Pharmaceuticals position peaked at $2.59M in Q4 2023.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.